Drug discovery has long been defined by time, cost, and repeated failure. Medvolt AI is using OpenAI-enabled intelligence to ...
Phase 1b norovirus challenge study is underway at Emory University School of MedicineCDI-988 is the first oral antiviral ...
AviadoBio Advances AVB-101 Gene Therapy Program and Initiates Fourth Dose-Escalation Cohort of Phase 1/2 ASPIRE-FTD Trial ...
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...
The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...
Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel ...
The Type C Meeting is part of a multidisciplinary strategy to seek alignment with the FDA on readiness to initiate a Phase 3 pivotal trial in MSA. Alterity received written feedback supporting its ...
Additional information about the 2026 AAN Annual Meeting is available at www.aan.com.
Inside a diseased cell, the genes are in chaos. Some are receiving signals to overproduce a protein. Others are reducing activity to abnormal levels. Up is down and down is up. The right molecule ...
A biotech spin-out from the University of Cambridge has secured £2.9m to scale its cell assay technology and remove bottlenecks in cell screening.
BullFrog AI (BFRG) stock jumped 106% after announcing a drug discovery deal with a top-5 pharma firm targeting major ...
The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results